Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
431. |
ECCT/16/12/02 | Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial. |
Principal Investigator(s) 1. ISAAC TSIKHUTSU Site(s) in Kenya KEMRI/WRP, KERICHO |
10-01-2017 |
View |
432. |
ECCT/16/12/01 | The Partners Scale-Up Project Animplementation project to scale-up delivery of antiretroviral-based HIV-1 prevention amongKenyan HIV-1 serodiscordant couples. |
Principal Investigator(s) 1. Prof. Elizabeth Ann Bukusi Site(s) in Kenya 1. KISUMU SITE (Kisumu county) 2. Thika Site (Kiambu county) |
13-02-2017 |
View |
433. |
ECCT/16/12/03 | The Partners Scale-Up Project An implementation project to scale-up delivery of antiretroviral-based HIV-1 prevention among Kenyan HIV-1 serodiscordant couples |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya 1. Thika Level 5 Hospital, Ruiru Sub-County Hospital, Kiambu County Hospital, Kikuyu PCEA Hospital (Kiambu county) 2. Coptic Hospital, Mbagathi Hospital, St. Mary\'s Hospital, Pumwani Maternity Hospital (Nairobi City county) 3. Nyeri PGH, Karatina Sub-County Hospital, (Nyeri county) 4. Kerugoya County Hospital (Kirinyaga county) 5. Murang\'a County Hospital (Murang\'a county) |
04-02-2017 |
View |
434. |
ECCT/17/03/03 | FLACSAM First Line Antimicrobials in Children with Complicated Severe Acute Malnutrition |
Principal Investigator(s) 1. James Berkley Site(s) in Kenya 1. Kilifi County Hospital (Kilifi county) 2. Coast General Hospital (Mombasa county) 3. Mbagathi Hospital (Nairobi City county) |
21-06-2017 |
View |
435. |
ECCT/16/11/04 | RV456 A Randomized, Observer-blind, Placebo-controlled, Two part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo |
Principal Investigator(s) 1. JANET OYIEKO Site(s) in Kenya KOMBEWA CLINICAL RESEARCH CENTRE |
28-01-2017 |
View |
436. |
ECCT/16/11/05 | RV 456: Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo A randomized, obsever-blind, placebo controlled, two-part, Phase 2 study to evaluate the Safety, Tolerability and Immunogenicity of Two prime-boost regimen of the candidate Prophylactic vaccines for Ebola Ad26-ZEBOV and MVA-BN Filo. |
Principal Investigator(s) 1. Fredrick Kipyego Sawe Site(s) in Kenya 1. KEMRI/WRP Kericho (Kericho county) 2. KEMRI/WRP Kombewa, Kisumu (Kisumu county) |
02-03-2017 |
View |
437. |
ECCT/16/11/03 | COAST Childrens Oxygen Administration Strategies Trial |
Principal Investigator(s) 1. Kathryn Maitland Site(s) in Kenya 1. Kilifi County Hospital (Kilifi county) 2. Coast Provincial General Hospital (Mombasa county) |
22-02-2017 |
View |
438. |
ECCT/16/09/03 | Effect of Schistosoma mansoni infection on incidence of Plasmodium falciparum malaria among 1-5 year old children in western Kenya. Effect of Schistosoma mansoni infection on incidence of Plasmodium falciparum malaria among 1-5 year old children in western Kenya. |
Principal Investigator(s) 1. Dr.Pauline NM Mwinzi Site(s) in Kenya KEMRI CGHR |
28-11-2016 |
View |
439. |
ECCT/16/11/02 | IMPAACT P1093 Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and AdolescentsPhase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents |
Principal Investigator(s) 1. Lucy Koech Site(s) in Kenya KENYA MEDICAL RESEARCH INSTITUTE/WALTER REED PROJECT HIV PROGRAME |
28-03-2017 |
View |
440. |
ECCT/16/10/02 | PAINT Study A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years |
Principal Investigator(s) 1. Professor Walter Jaoko Site(s) in Kenya 1. KAVI Institute of Clinical Research (Nairobi City county) 2. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county) |
13-02-2017 |
View |